To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
All releases
English
Initiator Pharma A/S – Resolutions of the annual general meeting 2022
The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 24 May 2022.
Correction: Initiator Pharma reports positive efficacy data outcome of the IPTN2021 program Phase I study to assess pain-reducing effects
Initiator Pharma A/S, a clinical-stage pharma company, announced today that analysis of the first data read-out has been obtained in the IPTN2021 program clinical Phase I study in healthy subjects dosed with the drug substance IP2015, and challenged with a pain-inducing ingredient (capsaicin).
Initiator Pharma reports positive efficacy data outcome of the IPTN2021 program Phase I study to assess pain-reducing effects
Initiator Pharma A/S, a clinical-stage pharma company, announced today that analysis of the first data read-out has been obtained in the IPTN2021 program clinical Phase I study in healthy subjects dosed with the drug substance IP2015, and challenged with a pain-inducing ingredient (capsaicin).
Board of Directors decides on execution of already communicated directed issue
The Board of Directors of Initiator Pharma A/S (“Initiator” or “the Company”) has today, 19 May 2022, based on the authorization from the recently held Extraordinary General Meeting, decided to execute the directed issue which was communicated via a press release on 13 April 2022. The directed issue was subscribed by Linc AB and Adrigo Asset Management AB, and it will provide the Company with approx. SEK 20 million before issue costs.
Correction: Resolutions at the Extraordinary General Meeting in Initiator Pharma A/S
Today, 18 May 2022, the Extraordinary General Meeting of Initiator Pharma A/S (the “Company”) was held. Below follows a summary of the adopted resolutions. All resolutions were adopted with the required majority of votes.
Resolutions at the Extraordinary General Meeting in Initiator Pharma A/S
Today, 18 May 2022, the Extraordinary General Meeting of Initiator Pharma A/S (the “Company”) was held. Below follows a summary of the adopted resolutions. All resolutions were adopted with the required majority of votes.
INITIATOR PHARMA: Q1 2022 REPORT
Business highlights in Q1 2022 On January 20th the initiation of dosing in the IPTN2021 program Phase 1 to assess pain reducing effects in healthy volunteers was announced. On March 22nd it was…
Correction: Initiator Pharma – Notice of Annual general meeting
Please note that the wording of new article 4.b in item 9.6 have been corrected on 29 April 2022 to reflect that the authorization in item 6.b is without pre-emption rights for existing shareholders…
Correction: Initiator Pharma – Notice of Annual general meeting
The previous notice was missing appendixes. The correct notice is as follows. The board of directors hereby convene the annual general meeting of Initiator Pharma A/S (the "Company") for…
Annual report 2021 for Initiator Pharma A/S
Initiator Pharma’s annual report for 2021 is now available on the company´s home page